Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139555 · ClinicalTrials.gov registry record · Phase 4
Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension
A Phase 4 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 4
- Development phase
- 125
- Enrollment target
NCT00139555 is a Phase 4 study that has completed, run by Novartis. The registered enrollment target is 125 participants.
The verdict
NCT00139555, a Phase 4 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 125 participants
- Enrollment target
Study Summary
Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will evaluate the effects of amlodipine/benazepril in reducing LVM in patients with high risk hypertension.
Interventions
- DRUG amlodipine/benazepril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139555
The ClinicalTrials.gov registry entry for NCT00139555 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which amlodipine/benazepril is the first listed.
NCT00139555 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00139555 about?
NCT00139555 is a clinical study titled "Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension". Left ventricular hypertrophy (LVH) increases the risk of cardiovascular morbidity and mortality in patients with high blood pressure, compared to those without LVH. Reduction of left ventricular mass (LVM) with antihypertensive agents is associated with improved clinical outcome. This study will eva...
What is the current status of trial NCT00139555?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 125 participants. The study started on 2004-07. Estimated completion is 2006-11.
What interventions are being tested in trial NCT00139555?
The interventions under investigation include: amlodipine/benazepril (DRUG).
Who is sponsoring clinical trial NCT00139555?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.